Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2), constitutes approximately 15-20% of all breast cancer (BRCA) cases (1). This evidence concerns the gene ERBB2 and breast carcinoma.